The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma

<div>Clinical course of the patient at relapse. (a) First early relapse showing bone marrow progression (Ann-Arbor IVB-E); (b) partial remission after 2 cycles of the first ICE salvage treatment, with faint uptake over the bone marrow; and (c) complete remission after 2 cycles of second salvage using the brentuximab vedotin-ESHAP protocol.</div>

Case Reports in Hematology

fig2

Figure 2

Figure 2: The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma 

Figure 2 | The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma 